1. Home
  2. CC vs BEAM Comparison

CC vs BEAM Comparison

Compare CC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chemours Company (The)

CC

Chemours Company (The)

N/A

Current Price

$11.66

Market Cap

2.3B

Sector

Industrials

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$25.80

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CC
BEAM
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CC
BEAM
Price
$11.66
$25.80
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
$17.00
$48.09
AVG Volume (30 Days)
2.4M
1.9M
Earning Date
11-06-2025
11-04-2025
Dividend Yield
2.99%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,837,000,000.00
$55,701,000.00
Revenue This Year
$3.34
N/A
Revenue Next Year
$4.20
$26.52
P/E Ratio
N/A
N/A
Revenue Growth
0.03
N/A
52 Week Low
$9.13
$13.53
52 Week High
$20.12
$35.25

Technical Indicators

Market Signals
Indicator
CC
BEAM
Relative Strength Index (RSI) 40.89 50.81
Support Level $11.55 $25.86
Resistance Level $13.42 $28.10
Average True Range (ATR) 0.63 1.66
MACD -0.03 0.03
Stochastic Oscillator 3.75 39.97

Price Performance

Historical Comparison
CC
BEAM

About CC Chemours Company (The)

The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: